pharma news, views and analysis

1200px-Human_Natural_Killer_Cell_(29120480442)

in News

New Nkarta data backs up natural killer approach to cancer treatment

December 5, 2022

New Nkarta data backs up natural killer approach to cancer treatment

https://pharmaphorum.com/news/new-data-backs-up-nkarta-natural-killer-approach-to-cancer/

Harnessing the power of natural killer (NK) cells to attack cancer is as-yet an unproven strategy in oncology

in News

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

December 5, 2022

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

https://pharmaphorum.com/news/novartis-pluvicto-presents-survival-benefit-for-castration-resistant-prostate-cancer/

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful

Latest News

GSK cancer division delivers good news after string of R&D setbacks

GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for

GSK cancer division delivers good news after string of R&D setbacks

https://pharmaphorum.com/news/gsk-cancer-division-delivers-good-news-after-string-of-rd-setbacks/

ViiV Healthcare study reveals outdated perceptions of HIV

New research from ViiV Healthcare has revealed a widespread gap in public knowledge and understanding of HIV worldwide,

ViiV Healthcare study reveals outdated perceptions of HIV

https://pharmaphorum.com/news/viiv-healthcare-study-reveals-outdated-perceptions-of-hiv/

AstraZeneca, MSD raise prostate cancer awareness with ‘Never Miss’ campaign

A new global prostate cancer awareness campaign developed by biopharmaceutical companies AstraZeneca (AZ) and Merck & Co. (MSD)

AstraZeneca, MSD raise prostate cancer awareness with ‘Never Miss’ campaign

https://pharmaphorum.com/news/astrazeneca-msd-raise-prostate-cancer-awareness-with-never-miss-campaign/

See all

Views & analysis

Company profile: NeoImmuneTech

NeoImmuneTech, Inc CEO: Dr Se Hwan Yang, PhD Headquarters: Rockville, MD, USA (2400 Research Blvd., Suite 250, Rockville,

Company profile: NeoImmuneTech

https://pharmaphorum.com/views-and-analysis/company-profile-neoimmunetech/

Meeting MSL training needs in an evolving landscape

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more

Meeting MSL training needs in an evolving landscape

https://pharmaphorum.com/oncology/meeting-msl-training-needs-in-an-evolving-landscape/

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

https://pharmaphorum.com/views-and-analysis/esmo-2022-paola-1-ovarian-cancer-and-treatment-innovation/

See all

Debates & Insights

Meeting MSL training needs in an evolving landscape

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more

Meeting MSL training needs in an evolving landscape

https://pharmaphorum.com/oncology/meeting-msl-training-needs-in-an-evolving-landscape/

ZS_webinar_holding_slide-approved_13.09.19

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Anthill_webinar_holding_slide-04_12_2018-ONE-NEW

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

See all

Partner Content

PM Society Digital Awards 2021

https://pharmaphorum.com/events/pm-society-digital-awards-2021/

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

Study to improve the life of cancer patients

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

https://pharmaphorum.com/partner-content/a-study-to-avoid-chemotherapy-in-patients-with-early-her-2-breast-cancer/

J+D Forecasting strike the balance for the liquid tumour market

Greater confidence in outputs and decision-making

J+D Forecasting strike the balance for the liquid tumour market

https://pharmaphorum.com/partner-content/jd-forecasting-strike-the-balance-for-the-liquid-tumour-market/

See all

Trending

Login